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Abstract 
Obesity is a complex disease that results from the interaction between lifestyle (dietary 
patterns and sedentary habits) and genetic factors. The recognition of a genetic basis for 
human obesity have driven to identify putative causal genes to understand the pathways 
that control body mass and fat deposition in humans as well as to provide personalized 
treatments and prevention strategies to fight against obesity. More than 120 candidate 
genes have been associated with obesity-related traits. GWAS (genome-wide 
association study) have so far identified over 20 novel loci convincingly associated with 
adiposity. This review is specifically focused on the study of the effects of MC4R, 
PPARγ and FTO gene variants and their interactions with dietary intake, physical 
activity or drug administration on body weight control. The advances in this field are 
expected to open new ways in genome-customized diets for obesity prevention and 
therapy following personalized approaches. 
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INTRODUCTION 
Obesity is a worldwide epidemic that predisposes to a high risk of premature mortality 
[1]. The increased incidence of obesity, particularly in Western societies, is considered 
to be the result of a change in lifestyle (i.e. less physical activity) and inadequate eating 
habits (i.e. high quantity and high energy-yielding foods [2], which leads to an increase 
in adipose tissue mass and fuel metabolism disturbances. However, there is evidence 
that within a population the variance in BMI (body mass index) is substantially 
genetically determined [3].  
The recognition of an important genetic influence on human obesity have lead to search 
causal genes in order to understand not only the pathways and networks that control 
body mass and composition in humans but also to provide insights that will contribute 
to improved treatment and prevention strategies [4]. 
Defining obesity 
Obesity is a complex disease, which results from an imbalance between energy intake 
and expenditure, producing an excessive fat depot accumulation [5]. Human adiposity 
resolves complex interactions among genetic, developmental, behavioural, and 
environmental influences [6]. 
Genetic factors are currently estimated to account for 40–70% of the variance in human 
adiposity [3]. Two complementary experimental designs have been applied to: the 
candidate gene approach and the genome-wide association study (GWAS) strategy. 
Candidate genes are selected to be screened for variants associated with obesity based 
on the putative role of these gene products on the physiology and molecular 
mechanisms involved in energy homeostasis [7-8].  
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IDENTIFYING RELEVANT GENE VARIANTS IN OBESITY 
Indeed, human obesity has a strong genetic component and many gene regions that may 
influence an individual's predisposition to gain weight are apparently not yet known. 
However, the study of extreme human obesity caused by single gene defects has 
troughed light on the long-term regulation of body weight [9]. Monogenic obesity 
disorders have confirmed that the hypothalamic leptin–melanocortin system is critical 
for energy balance in humans, because disruption of these pathways causes the most 
severe obesity phenotypes [2]. Approximately 20 different genes have been implicated 
in monogenic causes of obesity; however, they account for less than 5% of all severe 
obesity cases. This outcome suggests that the genetic basis for human obesity is likely 
to be very heterogeneous, with low contributions from numerous genes acting by 
various, yet mainly undiscovered, molecular mechanisms. Thus, in most cases, obesity 
has a polygenic background, having each causative gene variation a small relevance, but 
a considerable importance in the development of a personalized treatment [10].  
The characterization of potential pathways involved in the pathophysiology of the 
common forms of obesity by means of the identification of genes and mutations is far 
from being a reality in the majority of the cases.  Although, a few hundred of 
monogenic forms of obesity, caused by single-gene mutations, have been reported, the 
true number is assumed to be much larger. So far, eleven genes have been implicated in 
these single-gene cases [11]: CRHR1 (corticotrophin-releasing hormone receptor 1), 
CRHR2, MCHR1 (melanin-concentrating hormone 1), LEP (leptin), LEPR (leptin 
receptor), MC3R (melanocortin 3 receptor), MC4R (melanocortin 4 receptor), NTRK2 
(BDNF high-affinity receptor), POMC (proopiomelanocortin), PCSK1 (Prohormone 
convertase subtilisin/kexin type 1), and SIM1 (Single-minded 1). 
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However, most obesity cases are attributed to the interaction of multiple factors 
including polymorphisms on several genes. There are a number of studies that have 
analyzed multiple specific gene variants implicated in different biological processes. 
That is the case of mutations in genes encoding factors involved in the food intake 
regulation, such as NPY (neuropeptide Y) or ghrelin; implicated in energy expenditure, 
as ADRB2 (beta-adrenoreceptor) and 3 or UCP2 (uncoupling protein) and 3, in addition 
to genes controlling adipogenesis such adiponectin or FABP (fatty acid binding protein) 
[12].  
In the last years, an association between a low grade inflammation and the development 
of obesity has been described [13]. Thus, the activity of some cytokines secreted by the 
adipose tissue seems to be associated with pathways implicated in body weight 
regulation [14]. In this sense, variants on genes encoding these cytokines are being 
widely studied such as interleukin 6 (IL-6) gene polymorphisms [15-16]. 
The number of genes implicated in obesity is huge and increases very rapidly. In this 
review, we report findings and outcomes concerning the study of three well documented 
genes (MC4R, PPARγ and FTO) involved in body weight and energy homeostasis. The 
selection criteria were: the most important causative gene of monogenic obesity 
(MC4R), one of the most investigated gene in candidate gene studies and nutrigenetic 
studies (PPARγ), and the best example of a loci discovered by GWAS methodology and 
firmly associated with BMI (FTO). 
 Moreover, findings on the interactions of different gene variants and dietary 
components or drugs on the treatment of obesity are reviewed. 
Candidate gene association studies 
Candidate gene selection for the study of obesity is based on the knowledge of the 
biological and/or pathophysiological implication of the gene on this disease [17]. 
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Several genes have been analyzed on large populations or case control studies because 
of their implication on energy balance on animal models or extreme monogenic cases.  
The advances in the field have been very important in recent years reflected by the fact 
that the last update of the Human Obesity Gene Map (2006), reported 127 candidate 
genes for which at least one study described a positive association with obesity-related 
traits [18]. However, these genes appeared to have small effects in many cases but the 
variant allele is quite common in the population [11]. Moreover, for many of the 
potential candidate genes, replication in other studies has been often inconsistent, 
remaining the association not clear. The main problem of the low rate of replication of 
candidate gene approach seems to be the small sample size of the studies and 
environment influences [19]. In order to overcome this problem, in recent years, there 
have been an increasing number of large population studies and also meta-analysis 
studies of the available data (Table 1) [17].  
MC4R 
Obesity-related genes participating in neurohormonal pathways frequently have 
reciprocal effects on energy intake and expenditure, although their primary effect 
appears to be on the regulation of appetite and satiety [9]. In this sense, the 
melanocortin 4 receptor (MC4R) is a strong obesity candidate gene. This receptor is a 
332-amino acid protein encoded by a single exon on chromosome 18q22 [20-21] and is 
widely expressed in the brain. The endogenous ligand for MC4R is the α-melanocyte 
stimulating hormone (a-MSH). MC4R mutations have been associated with inherited 
severe obesity in humans [22-23]. Tao et al. (2003), proposed a five-type classification 
of MC4R mutations: truncated nonfunctional receptors, intracellularly trapped mutants, 
binding defective mutants, signalling defective mutants, and those with unknown 
defects [21]. More than 100 variants in human MC4R have been reported up to date 
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[24]. About 50% of these variants have a partial or complete impairment or loss of 
function in vitro [25]. Although defects in MC4R seems to constitute the most common 
form of monogenic obesity, prevalence rates ranging from 0.5% to 5.8%, [26-27], 
different penetrance or expressivity of the mutations and potential environment 
interactions configure a variety of obesity phenotypes [24].  The features concerning 
MC4R deficiency are characterized by several disorders such as hyperphagia, 
hyperinsulinemia or increased fat mass [2].  
The importance of the MC4R mutations in the development of obesity has been 
confirmed by researches regarding large populations (meta-analysis) and in the high 
number of emerged loci in GWAS studies [28-30].  
PPARγ 
Peroxisome proliferator-activated receptor γ (PPARγ) encodes a transcription factor 
(PPAR γ2) that controls the expression of genes involved in adipocyte differentiation, 
lipid storage, and insulin sensitization [31]. This gene is one of the most studied as 
potentially linked to the development of obesity, and especially related to the 
interactions with lifestyle factors [6, 32-36]. 
To date one common variant (Pro12Ala) and 16 rare missense and nonsense mutations 
in the coding region of the PPARγ gene have been identified and functionally analysed 
[37] The Pro12Ala polymorphism of the PPARγ2 protein is the most frequently found 
genetic variant of PPARγ, whose frequency has been reported to vary from 2% to 25% 
depending on ethnicity (table 2). 
The effects of the 12Ala allele have been studied in functional analysis revealing that 
the receptor expressing this allele displays reduced DNA (deoxyribonucleic acid)-
binding affinity and impaired transcriptional activity in target genes [38]. Therefore, the 
12Ala carriers would be expected to be protected against excessive adiposity due to the 
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reduced functionality of the receptor. However, there are studies in human subjects 
showing that the 12Ala allele was associated with increased adiposity [39-41]. These 
contradictory in vitro and in vivo results might be explained by a potential enhancing 
effect of the anti-lipolytic action of insulin, which leads to reduced release of free fatty 
acids [38]. Moreover, conflicting results in human studies could lead to think that 
Pro12Ala may be interacting with some factors. Indeed, giving these differential effects, 
mechanistic studies are needed.  
A summary of the positive, nule and negative associations of the polymorphism with 
obesity found in Caucasian populations is reported (table 2).  
Genes identified by GWAS 
Genome-wide association studies had made a reality the challenge to analyze DNA 
sequence variants of large populations in a single experiment. The first study using this 
technology was published in 2005 [42], and the first analysing a complex disease, type 
2 diabetes, in 2007 [43]. The genome-wide association approach looks into the entire 
genome, without any previous consideration. The aim is to identify genetic loci, not a 
priori considered as an implicated region, associated with a disease phenotype. This 
approach may help to clarify the knowledge of the underlying patophysiology. 
Thus, the advantages and benefits of performing a GWAS are clear: the entire genome 
of thousand samples can be analyzed in a single assay. Despite the strength of the 
approach it has some limitations that need to be explained. First of all it has to be 
considered the possibility of false positives due to multiple testing. Moreover, in the 
case of complex disease as obesity, the heterogeneity of the trait gets more difficult the 
finding of specific SNPs.  Another limitation is that GWAS consider only common 
SNPs, thus the contribution of many rare SNPs to the trait may remain ignored [44-45].  
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Anyway, GWAS have revolutionized the field of genetic epidemiology and has already 
resulted in an unprecedented chain of discoveries with >300 replicated associations for 
>70 common diseases and traits [17]. This approach have so far identified over 20 novel 
loci , including genes as FTO or the region near MC4R, robustly associated with obesity 
traits, revealing that GWAS is the most productive approach compared to the other 
gene-discovery methods previously used for common traits [46]. 
FTO 
Approaches based on GWAS have identified common genetic variants that are robustly 
associated with higher BMI in adults. To date, FTO (fat mass and obesity associated) 
gene polymorphisms appears to have the most important effects on obesity 
susceptibility [46]. A GWAS initially performed for type 2 diabetes screening identified 
a common variant in FTO (rs9939609), which conferred increased risk for diabetes 
secondary to its associations with greater body mass index (BMI) in the adult [47]. 
Simultaneously, another GWAS in relation to BMI confirmed the association between 
FTO gene variants and this adiposity index [48]. 
The FTO gene is composed of nine exons that span more than 400 kb on chromosome 
16. Several SNPs were initially identified by Frayling et al.[47], Dina et al. [49] and 
Scuteri et al.[48]. They are located in the first intron of the gene, a region where the 
sequence is strongly maintained across species. It is known that FTO encodes a 2-
oxoglutarate-dependent nucleic acid demethylase, and that it is located in the nucleus 
[50]. The biological action of FTO in humans remains to be fully established [51], 
although there is increasing evidence for associations between FTO genotype and 
differences in eating behaviour, satiety and dietary intake, but not in energy 
expenditure, at least in children [52-53]. The most studied variant in FTO gene is the 
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rs9939609 T/A that has been associated with higher body weight and [52-53] higher 
risk of obesity in different studies and populations [47-48, 54-56].  
This polymorphism is currently being widely studied in children cohorts due to its 
potential implication in the development of obesity at this early stage [57]. Thus, a 
summary of the association between rs9939609 and obesity as found in children studies 
is shown (table 3).  
 
The identification of implicated loci in BMI variation has lead to the study of new 
genetic areas. However the analysis of the genetic predisposition of individuals for 
obesity taking into account these loci has revealed that they explain a low percentage of 
variance in BMI. In this sense, the combination of the additive risk of two common 
variants in FTO and near MC4R genes widely associated with BMI, account for less 
than 2% of the variance in adult BMI in a 77000 subjects population [8, 29, 47]. When 
the effect of other discovered loci as are considered, this percentage does not improve 
[30], suggesting that although FTO and MC4R are highly associated with BMI they can 
not explain per se the development of obesity.  
 
Prevention and treatment based on genotyping 
Current obesity investigations based on genotyping are directed to prescribe a 
personalized treatment. Indeed, obesity is infrequently originated by one gene 
(monogenic obesity), and usually depends on various factors such as several gene 
variations and their interactions with lifestyle factors. Thus, the prevention and 
treatment of obesity must be independently considered in each case considering the 
individual’s potential response to lifestyle modification or drug treatment depending on 
the genotype. 
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Nutrigenetics 
Nutrigenetics is a growing science that studies the response of individuals to a dietary 
component or components depending on the genotype [58-59]. There are some studies 
analyzing the interaction between dietary components or dietary patterns and genetic 
variants on adiposity. Most of these studies are conducted within crossectional designs. 
However, the best approach to analyze the effects of a mutation on obesity parameters 
appears to be on the frame of a nutritional intervention [60-61].  
Probably, the most studied gene in relation to the interactions with dietary components 
on adiposity features is the PPARγ, and specifically the Pro12Ala gene variant (table 4). 
The majority of the studies have been directed to the interaction between fat intake and 
Pro12Ala due to the fact that free fatty acids are natural agonists of the PPARγ 
transcription factor [62]. Nevertheless, the relationship between the variant and 
carbohydrate intake or alcohol consumption have been also analyzed in different studies 
[33, 35, 63].  
Related to the total fat intake, in the Quebec Family Study population (2003), an 
interaction between the Ala12 variant and total fat intake associated with higher BMI 
and waist circumference was found [64]. Memisoglu et al. (2003), found a significant 
interaction between total fat intake and BMI. The highest quintile of total dietary fat 
was associated with increased risk of obesity among Pro12Pro subjects [34]  
Related to unsaturated fatty acids, Luan et al. (2001) found that Ala12 carriers showed 
an inverse association between the dietary polyunsaturated to saturated fatty acids ratio 
(P:S) with BMI [32]. In this sense, Franks et al. (2004) reported that carriers of the 
Ala12 allele, who had high dietary P:S and were physically active, had lower fasting 
insulin levels [65]. Moreover, in a case-control study, Ala12 carriers with increasing 
intake of arachidonic acid presented a higher risk of obesity [35]. Furthermore, 
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Memisoglu et al. (2003), found that intake of monounsaturated fatty acids (MUFA) was 
inversely associated with BMI in Ala12 allele-carriers but not in Pro/Pro homozygotes, 
in a larger population [34]. Aditionally, Soriguer et al. (2006) found that the low 
consumption of MUFA in obese Ala carriers was associated with higher HOMA values 
in a healthy Spanish population [66].   
Apart from fat intake, Marti et al. (2002) reported an increased obesity risk for Ala12 
carriers when consuming more than 49% of total energy from carbohydrates [33]. 
Furthermore, other studies have analyzed the association of the polymorphism and 
alcohol intake. Results obtained by the European Project on Genes in Hypertension 
showed that elevated alcohol consumption in Ala12 carriers was associated with higher 
serum HDL cholesterol levels [63]. 
Recently, a substudy of the PREDIMED intervention trial, found that a Mediterranean 
dietary pattern rich in virgin olive oil or nuts was able to reverse the negative effect that 
the12 Ala allele had in waist circumference. Thus, 12Ala carriers that consumed a 
Mediterranean-style diet during 2 years had similar waist circumference enlargement 
compared to Pro12Pro subjects. In contrast, 12 Ala carriers that followed a conventional 
low fat diet had a significantly higher waist circumference compared to non mutated 
subjects [67].  
Moreover, also in a recent trial with Pro12Ala mutant knock in mice, it was 
demonstrated that the effects of PPARγ Pro12Ala variant on metabolic control is diet-
dependent, especially when comparing dietary fat content [68]. 
Currently, the most studied gene in relation to the interactions with lifestyle factors is 
the FTO gene, and especially the rs9939609 variant. Related to dietary interactions, 
Sonestedt et al (2009) found in a crossectional study that there was a significant 
interaction between fat intake and FTO genotype and also between carbohydrate intake 
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and FTO genotype on BMI [69]. There are also some nutritional intervention studies 
analyzing interactions with this gene variant [55, 70]. However, most of the 
interventional studies are directed to a complete lifestyle intervention including physical 
activity and dietary changes especially in children [54, 71-72]. 
Physical activity-genotype interactions 
The diagnosis of interactions between physical activity level and gene variants tries to 
find a personalized therapy for subjects genetically predisposed to develop obesity. 
Given the fact that the FTO gene appears might participate in controlling energy 
expenditure, variations on this gene are receiving attention in the study of gene 
variation-lifestyle interactions on body weight. Therefore, the outcomes obtained up to 
now related to the interactions between FTO gene variants and physical activity on 
children and adult populations are reviewed (table 5). 
In this context, concerning the rs9939609 Hakanen et al., did not find any significant 
association between leisure time physical activity in an adolescent cohort of the STRIP 
study [54]. In contrast, Ruiz et al, found that the rs9939609 was associated with higher 
BMI, body fat and waist circumference but this effects were attenuated in adolescents 
who met the daily recommended physical activity [73]. 
In adults, Andreasen et al. (2008), found that physical inactive Danish subjects carrying 
the A risk allele had higher BMI compared to wild type subjects (TT), suggesting that 
low physical activity may accentuate the effect of FTO rs9939609 on body fat 
accumulation [74]. However, three adult studies in other European populations [70, 75-
76], found no evidence of interaction between physical activity and this FTO gene 
variant on body weight (Table 5). 
Other FTO gene variants have been investigated in relation to their interactions with 
physical activity on BMI. Thus, Mitchell et al. (2009), found that the A allele of 
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rs8050136 gene variant was associated with higher BMI at baseline, but after following 
the physical activity recommendations of the intervention program, AA subjects were 
found to have a higher weight loss in comparison to CC subjects [77]. In the EPIC-
Norfolk cohort, Vimaleswaran et al (2009), found that T risk allele of rs1121980 was 
associated with BMI and waist circumference, but physical activity level was able to 
attenuate this effect [78]. Moreover, Rampersaud et al (2008), found that two FTO gene 
variants, rs1477196 and rs1861868, were associated with BMI and obesity only in those 
subjects with a low level of physical activity [79] (Table 5). 
Drug-genotype interactions  
The increasing epidemic of obesity is leading to look for new strategies on the 
prevention and treatment of this disease. The first approach is to configure lifestyle 
patterns (including dietary and physical activity changes), however, long-term lifestyle 
modification suffer from lack of individual’s compliance. Moreover, subjects with a 
potent genetic susceptibility need even more than a radical lifestyle change [80]. In this 
context, pharmacotherapy appears to be a suitable approach to treat obesity. Three 
common drug therapies have been applied in the treatment of obesity: orlistat, a lipase 
inhibitor, rimonabant, a selective cannabinoid-1 receptor antagonist, and sibutramine, a 
central appetite suppressant. However, only the first one can be now prescribed to fight 
against obesity in Europe. There are several genes that can be considered good targets 
for this therapy, but it remains important to take into account gene variants that may 
modify the effect of the potential therapy. Indeed, pharmacogenetics is the study of how 
genetically determined variations affect an individual's response to drugs. It is well 
known that adverse side effects and therapeutic failure of drugs may both have a strong 
genetic component [81]. 
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Sibutramine, a noradrenergic and serotonergic reuptake inhibitor, has been administered 
for the long term treatment of obesity [82]. Sibutramine induces satiety, prevents 
decline in metabolic rate associated with hypocaloric diets and causes weight loss 
especially when combined with behavioral therapy. Furthermore, there are large 
differences in weight loss among individuals treated with sibutramine. Thus, there were 
studies analyzing the potential interactions between this drug and gene variants that may 
affect weight loss. Grudell et al. (2008) found that sibutramine interacted with specific 
markers of candidate genes controlling serotonergic and adrenergic mechanisms (α2A-
receptor, 5-HTTLPR (serotonin-transporter-linked promoter region) and GNβ3 (G-
protein β subunit polypeptide 3). Treatment with sibutramine resulted in significantly 
greater reduction of weight and body fat for specific α2A CC and GNβ3 TC/TT 
genotype variants [83]. Furthermore, Vazquez Roque et al. (2007), also found that 
response to sibutramine was mediated by the SLC6A4 (solute carrier family 6 member 
2) genotype [84]. Anyway, as stated before, the prescription of this reuptake inhibitor 
has been forbidden, in Europe, since January 2010. 
Although sibutramine was used as a possible treatment for obesity, there are other 
studies looking for new therapies and, of course, studying the potential interactions with 
gene variants. In an interventional study with lifestyle modifications and capsinoid 
administration, Snitker et al. 2009, found that the 585Ile allele of TRPV1 (transient 
receptor potential cation channel) gene and -866A allele of UCP (uncoupling protein) 
gene are associated with a higher abdominal fat reduction [85]. On the other hand, 
Spraggs et al. (2005), evaluated the efficacy of GW320659 ((2S,3S,5R)-2-(3,5-
difluorophenyl)-3,5-dimethylmorpholin-2-ol), a highly selective neuronal 
norepinephrine and dopamine re-uptake inhibitor, in the treatment of obesity. They 
found that polymorphisms in SLC6A2  and GRIN1 (glutamate receptor, ionotropic, N-
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methyl D-aspartate 1) were associated with increased weight loss when treated with 
GW320659 [86]. 
All these results suggest that the study of potential interactions between specific 
polymorphisms and drugs could be used to maximize effective obesity 
pharmacotherapy by identifying patients that may be predisposed to a particularly 
treatment weight loss response. 
Conclusions and future of individualized treatments of obesity  
Obesity is actually a multifactorial disease and, consequently, involves a complex 
prevention and/or treatment strategies, which means that there is no universal treatment 
that would be beneficial for every obese patient. All the published studies to date are 
giving light to the fact of needing a personalized treatment for each obese subject. 
As the genetic contribution to the variance in human adiposity is estimated to account 
40-70%, it is clear that the prescription of future individualized treatments may need the 
knowledge of the subject genotype. For this purpose it is important to know now those 
genes and gene variations that are really important to take into account within a 
customized therapy. Furthermore, it would be essential to assess if there are interactions 
with the individual genotype and potentially modifiable lifestyle factors, especially 
dietary components and physical activity, and/or with potential drug treatments. 
Moreover, intervention studies have to be carried out on a large number of individuals 
to find robust results because of the small implication of each single SNP on body 
weight control. 
Moreover, to design an individualized nutrition other factors may have to be considered 
as epigenetics or nutrigenomics. Epigenetics has been defined as the study of heritable 
changes in gene expression that occur in the absence of a change in the DNA sequence 
itself. Increasing evidence indicates that early metabolic programming contributes to 
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increasing obesity prevalence in children and adults. Metabolic imprinting is involved 
in the establishment of set points for physiological and metabolical responses in 
adulthood. Recent studies suggest that changes in the dietary pattern may modify the 
imprinting.  
Considering the results of nutrigenetic, nutrigenomic and epigenetic studies, a 
personalized intervention for the patient may be defined in the future. At present, it 
seems an optimistic view, but i.e. there are trials seeking to design DNA microchips that 
may be used to identify the more relevant mutations in the development of obesity and 
treatment outcomes. 
It seems evident, that individuals genetically predisposed to obesity are going to benefit 
more from a specific treatment than subjects less susceptible that are benefited from 
standard treatments. Indeed, the high and increasing prevalence of obesity reveals that 
traditional treatments do not lead to a successful result in many cases. 
At present, the best therapy appears to be a combination of modification in dietary 
habits and physical activity level and, in severe obesity cases, the application of drug 
treatment according to subject genotype. But in the future, it is expected that genotype 
based interventions will be more relevant on the customized obesity therapy.
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